BD invests $110m to expand US prefillable syringe production

Core Insights - BD (Becton, Dickinson and Company) has announced a $110 million investment to expand its production of prefillable syringes in the US, aiming to strengthen the pharmaceutical supply chain and accelerate the delivery of biologic and GLP-1 drugs [1][5] Investment Details - The investment includes $100 million allocated for establishing the Neopak Glass Prefillable Syringe production line at the Columbus, Nebraska facility, with supply expected to begin by mid-2026 [2] - An additional $10 million will enhance cannula manufacturing capabilities, creating approximately 120 new jobs at the site [3] Facility and Production Capacity - The Columbus facility has been part of BD's global manufacturing network for over 75 years and includes vertically integrated cannula design and production operations [4] - These investments are part of BD's broader plan to invest over $2.5 billion in US manufacturing over five years, aimed at enhancing supply chain resilience as demand for biologics and combination products increases [4] Strategic Goals - BD's investment reflects its commitment to supporting US-based drug delivery innovation and partnering with biopharmaceutical innovators to deliver advanced therapies to patients [5]